- Location
- Zoom
- Series/Type
- Alumni Event, DLSPH Event, Faculty/Staff Event, Student Event
- Format
- Online
- Dates
- July 24, 2025 from 8:00am to 9:30am
Links
Presented by the Collaborative Centre for Climate, Health & Sustainable Care at UofT …
In August 2025, the Intergovernmental Negotiating Committee will reconvene to continue negotiations around an international legally binding instrument on plastic pollution (INC-5.2). Among the key areas under negotiation are the treaty’s approach to health and whether and how the precautionary principle and scientific evidence should guide decision-making and implementation. One specific paradox the treaty could address is that despite the risks to health posed by the risks of plastics to health and the environment, healthcare has increasingly become reliant on plastics in the design, manufacture, and packaging of health products. Thus, the plastics treaty must recognize the importance of ensuring equitable access to safe, effective, and quality-assured health products while also mitigating potential risks and harms from plastics.
However, for successful treaty implementation, we will need to chart a research agenda; evidence-to-decision frameworks to support policy and regulatory action; and governance processes that engage the multiple and diverse interest holders. In this workshop, hosted by the WHO Collaborating Centre for Governance, Accountability and Transparency in the Pharmaceutical Sector and the Collaborative Centre for Climate, Health, and Sustainable Care, we bring together WHO leadership and international experts to introduce useful frameworks and their application.
Featuring:
- Mr. Deusdedit Mubangizi, World Health Organization
- Dr. Quinn Grundy, University of Toronto
- Dr. Nicholas Chartres, University of Sydney
- Dr. Jeremy Greene, Johns Hopkins University
- Dr. Fiona Miller, University of Toronto
This event is a collaboration between the Collaborative Centre for Climate, Health & Sustainable Care and the WHO Collaborating Centre for Governance, Accountability and Transparency in the Pharmaceutical Sector.
